Bayer Reports 4.3% Q1 Revenue Decline and Announces 1,500 Job Cuts Amid Strategic Restructuring

On May 14, Bayer disclosed its Q1 2024 financial report, announcing a workforce reduction of approximately 1,500 positions, mostly in management, amid a slight decline in sales, while also revising downward its full-year profit outlook.

Q1 Revenue Misses Expectations

According to its financial report, Bayer achieved sales of over 14.86 billion US dollars in the first quarter, a year-on-year decrease of 4.3%. After adjustments for currency and portfolio effects, Bayer's year-on-year decline slowed to 0.6%. Among Bayer's three business divisions, only the pharmaceuticals division saw sales growth in the first quarter, while the Crop Science Division and Consumer Health Division experienced declines in both sales and earnings.

Image Source: Bayer Official Website

Bayer’s pharmaceuticals division delivered strong performance this quarter, with sales growing nearly 4% to over $4 billion after adjustments for currency and portfolio effects. The company attributed this growth to the significant success of its new products Nubeqa (darolutamide) and Kerendia (finerenone), the former being used for specific types of prostate cancer and the latter approved for treating chronic kidney disease in patients with type 2 diabetes.

In the first quarter, sales of Nubeqa surged 59% to nearly $306 million, while Kerendia’s sales grew 63.5% to reach $56 million.

Despite a slight decline in revenue, the anticoagulant Xarelto (rivaroxaban) and the ophthalmology treatment Eylea remained Bayer's top-selling products this quarter, generating approximately $1 billion and $844 million in revenue, respectively. Driven by increased volume and price hikes, Eylea’s sales grew by 3.4% (adjusted for currency and portfolio effects).

Imaging diagnostics also saw growth, with both the CT high-pressure injection systems product line and the Ultravist® product series achieving approximately 10% growth (after adjustments for currency and portfolio).

Despite the impact of generic drug competition, the sales of the oral anticoagulant Xarelto® still increased by 1.7% (after adjustment for currency and portfolio), in line with expectations. By contrast, unfavorable factors for the pharmaceuticals business include a decline in Adalat® (Nifedipine Controlled-Release Tablets) sales in China due to tendering procurement. Globally, sales of cardiovascular drugs decreased by 23.0% (after adjustment for currency and portfolio).

Looking Ahead to the Second Half of 2024, Bayer Lowers Its 2024 Earnings Per Share Guidance Range from the Previously Announced $5.35 to $5.78 to $5.19 to $5.62

Cut 1,500 jobs

While disclosing the financial report, Bayer also announced layoffs, with 1,500 jobs already cut.

CEO Bill Anderson revealed during the media teleconference on the same day that approximately two-thirds of the layoffs are management positions.

Anderson noted that Bayer's senior leadership circle has shrunk significantly compared to a year ago, and added that the layoffs will help the company achieve its goal of saving €500 million (US$540 million) in costs by 2024 and €2 billion (US$2.16 billion) by 2026.

Since taking over Bayer in June 2023, Anderson has been trying to reverse the catastrophic situation caused by the company's ill-fated $63 billion acquisition of agricultural giant Monsanto in 2016, which led to a $300 billion loss in Bayer's valuation following the announcement of the acquisition.

In January 2024, Anderson launched a new operating model aimed at maximizing operational efficiency and reducing corporate bureaucracy and hierarchy. The new model, called "Dynamic Shared Ownership (DSO)," is a radical restructuring initiative that includes layoffs through 2025.

In March 2024, Bayer streamlined its executive team, eliminating six positions from the leadership team of its pharmaceuticals division, reducing the number of senior executives from 14 to 8.

Summary

Bayer CEO Outlines Strategic Focus on Growth & Innovation, U.S. Litigation, Cash, and Deleveraging; Whether Bayer Can Turn Things Around in the Next Cycle Remains to Be Seen.

Source:

1. Bayer Official Website

2.https://www.biospace.com/article/bayer-cuts-1-500-jobs-lowers-2024-earnings-guidance-as-q1-sales-dip-/

Editor: Pea Shooter

Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of Pharma Intelligence. We welcome exchanges and additional insights in the comment section; for reprints, be sure to credit the author and source. If the content, copyright, or other issues are involved, please leave a message on this platform, and we will address it promptly.